文献速递哮喘慢阻肺

哮喘与慢阻肺的气道黏液栓:病理生物学、影像学及临床试验意义

Airway mucus plugs in asthma and chronic obstructive pulmonary disease: pathobiology, imaging, and implications for clinical trials.
PubMed 文献 · Am J Respir Crit Care Med · 2026-01-01

本文综述了哮喘和慢阻肺中气道黏液栓的形成机制、影像学评分方法及其临床意义。黏液栓负荷与哮喘和慢阻肺的急性加重、肺功能下降相关,在慢阻肺中还与死亡率增加相关。黏液栓负荷已作为临床试验终点评估生物制剂疗效,多项生物制剂显示可减少黏液栓负荷并改善肺功能。

要点

  • 黏液栓负荷与哮喘和慢阻肺急性加重及肺功能下降相关,慢阻肺中与死亡率增加相关。
  • 支气管肺段黏液栓评分等系统已用于关联黏液栓负荷与不良临床结局。
  • 黏液栓负荷可作为生物制剂治疗哮喘的临床试验终点,且CT检测已可用于临床和研究。

核心结论

  • 黏液栓可能是哮喘和慢阻肺的可治疗特征,具有临床、表型和预测效用,并有望成为未来生物标志物。

研究设计与样本

  • 综述,检索范围未明确报告。

主要发现

  • 黏液栓形成由黏液高浓度、黏液黏弹性改变、清除受损和黏液纤毛塌陷驱动。
  • 支气管肺段黏液栓评分等系统将较高黏液栓负荷与不良临床结局关联。
  • 黏液栓负荷与哮喘和慢阻肺的急性加重增加和肺功能下降相关,慢阻肺中与死亡率增加相关。
  • 多项生物制剂治疗哮喘显示黏液栓负荷减少及肺功能改善。

关键数值与推荐

  • 支气管肺段黏液栓评分用于关联黏液栓负荷与临床结局。
  • 基于定量图像处理的其他评分方法正在开发中。
  • CT检测黏液栓负荷已准备好更广泛地纳入研究结局和临床护理。

临床怎么用

  • CT检测黏液栓负荷可纳入临床护理和研究结局。
  • 黏液栓负荷可作为临床试验终点评估生物制剂疗效。

局限性

  • 需要更多纳入临床试验、扩展治疗效应证据以及标准化方法和成像方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mucus plugs have been previously recognized as an important pathological feature in asthma and chronic obstructive pulmonary disease (COPD), but their clinical role in these diseases has not been explored in depth until recently. Mucus plug formation is driven by mucus hyperconcentration, changes in mucus viscoelastic properties, impaired clearance, and mucociliary collapse. Scoring systems, such as the bronchopulmonary segment mucus plug score, have been used to associate greater mucus plug burden with poor clinical outcomes. Additional scoring methods obtained through quantitative image processing are currently under development. Mucus plug burden has been associated with greater exacerbations and spirometric decline in both asthma and COPD, as well as greater mortality in COPD. Recently, mucus plug burden has been used as an endpoint in clinical trials to evaluate the effectiveness of biologic therapies in asthma; multiple biologic therapies demonstrated decreases in mucus plug burden and associated improvements in spirometry with treatment. Together, these data suggest that mucus plugs may be a treatable trait in asthma and COPD. Mucus plug burden has current clinical, phenotypic, and predictive utility and shows promise as a future biomarker. Increased incorporation into clinical trials, expanded evidence of treatment effect, and standardization of methodology and imaging protocols will be needed. Computed tomographic detection of mucus plug burden is ready for greater incorporation into both research outcomes and clinical care.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Bosma CB, Aaron SD, Celli BR, et al. Airway mucus plugs in asthma and chronic obstructive pulmonary disease: pathobiology, imaging, and implications for clinical trials. Am J Respir Crit Care Med. 2026. PMID: 42330343. doi:10.1093/ajrccm/aamag309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。